摘要 : Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged >= 12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/2... 展开 Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged >= 12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died. Over 15 million US children have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19) [1]. While most children with COVID-19 are asymptomatic or have a mild illness, some develop severe disease. Pediatric risk factors for hospitalization and death include age < 1 year, obesity, diabetes, sickle cell disease, immunocompromising conditions, congenital or acquired heart disease, and chronic respiratory, kidney, and neurodevelopmental disorders [2]. COVID-19 vaccination, authorized in the United States for children >=6 months old, remains the most effective approach for the prevention of severe disease. However, vaccine immune responses may be inadequate in some children, while others may acquire infection before the completion of vaccination. Children >=12 years of age and weighing >=40 kg who have mild to moderate COVID-19 and comorbidities associated with severe disease are eligible for virus-neutralizing monoclonal antibodies (mAbs) under Emergency Use Authorizations (EUAs) issued by the US Food and Drug Administration (FDA). 收起